Pokhriyal Ruchika, Hariprasad Roopa, Kumar Lalit, Hariprasad Gururao
Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
Division of Clinical Oncology, National Institute of Cancer Prevention and Research, Noida, India.
Biomark Cancer. 2019 Jul 5;11:1179299X19860815. doi: 10.1177/1179299X19860815. eCollection 2019.
Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.
卵巢癌是女性中第七大常见的妇科恶性肿瘤。大多数卵巢癌患者在晚期被诊断出来，预后较差。晚期卵巢癌的标准治疗包括肿瘤减灭术，随后进行化疗。已使用多种化疗方案来治疗晚期卵巢癌，但最有前景且目前使用的标准一线治疗是卡铂和紫杉醇。尽管这种化疗组合改善了临床反应和生存率，但许多患者由于化疗耐药性而复发或死于该疾病。为了在细胞水平上理解这一现象，已开发出各种大分子，如DNA、信使RNA和蛋白质作为化疗反应的生物标志物。本综述全面总结了晚期卵巢癌中与化疗耐药性相关的问题，并对该领域已开发的各种生物标志物进行了很好的概述。
